induces enhanced proliferation and transcriptional activity to a similar level as observed after CD3 and CD28 co-crosslinking, demonstrating that CD6 is an important co-stimulatory molecule. The stability of ALCAM-CD6 binding, which contrasts with transient homotypic ALCAM-ALCAM interactions, further supports the long-lasting effects observed on T cell proliferation. Taken together, we demonstrate that CD6 and ALCAM form a key adhesive receptor-ligand pair that is not only involved in early DC-T cell binding but also in sustaining DC-induced T cell proliferation long after the initial contact has been established.
INTRODUCTION
The interaction between a T cell and an antigen-presenting cell (APC) is the central event in the induction of an adaptive immune response and involves different and sequential cellular events.
Initially the T cell transiently adheres to the APC and scans its surface for the presence of specific peptide-MHC complexes in an antigen-independent manner. Several receptor-ligand pairs such as CD2/LFA-3, LFA-1/ICAM-1,-3 and ICAM-3/DC-SIGN have been implicated in these early T cell-APC interactions 1 . In particular ICAM-1 and -3 play a key role in mediating the initial, antigenindependent adhesion of T cells and APC 1, 2 . Once the initial contact has been generated, the contact interface is stabilized by molecular reorganization of antigen-receptors, adhesion molecules, costimulatory molecules and the actin cytoskeleton. This highly organized supra-molecular structure is known as the immunological synapse 3 . Adhesion molecules and TCR-associated components are , but also heterotypic interactions with the T cell antigen CD6 have been described 7 .
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Its extracellular region contains three scavenger receptor cysteine-rich (SRCR) domains, thus including CD6 into the SRCR superfamily of protein receptors 14 . To date, ALCAM is the only CD6 ligand identified on immune cells. Although the precise function of CD6 remains to be elucidated, several studies point towards a role for CD6 as a co-stimulatory molecule in T cell activation [15] [16] [17] . CD6
may exert its function via association with CD5, another co-stimulatory molecule and member of the SRCR superfamily that co-precipitates with CD6 in lymphoid T cells 18 . It has been suggested that CD6 fine-tunes CD5 tyrosine phosphorylation by recruiting specific kinases of different families, such as Itk and Lck
19
. CD6 physically associates with the TCR/CD3 complex, it relocalizes upon T cell activation at the cSMAC and it modulates immunological synapse maturation in a Jurkat-Raji model system 20 . Direct evidence showing that CD6 and its ligand ALCAM play a role in mediating contact between resting T lymphocytes and DCs has not been documented. This, and the high expression of ALCAM on monocyte-derived DCs, prompted us to investigate the importance of CD6 and ALCAM in DC-T cell contact initiation, co-stimulation, and in the proliferative phase of the T cell response.
Both ALCAM and CD6 are actively recruited at the T cell-APC interface and contribute to stabilization of the immunological synapse. Moreover, long-term ALCAM-CD6 interactions proved to be crucial for T cell proliferation and CD6 induces co-stimulatory signals. We conclude that ALCAM-CD6 mediated adhesion contributes to both early and later stages of DC-induced T cell activation and proliferation. CD6 (5 μg/ml), LFA-1 (NKI-L15, 10 μg/ml), or recombinant ALCAM-Fc and CD6-Fc proteins (10 μg/ml) were added at co-culture onset. Total mouse IgG and unrelated L-SIGN-Fc protein were used as negative controls. Alternatively, T cells were stimulated with immobilized anti-CD3 (OKT-3, 0.2 μg/ml), either or not in combination with anti-CD28 (4 μg/ml) or anti-CD6 (5 μg/ml), followed by 
NFAT reporter gene assay
Round-bottom 96-well plates (Costar, Corning, NY) plates were pre-coated for 16 h at 37°C
with anti-CD3 (OKT-3, 1 μg/ml) or control mouse IgG in combination with anti-CD28 (4 μg/ml) or anti-CD6 (1 or 5 μg/ml). Jurkat T cells were transfected by Amaxa Nucleofector TM technology with a pNFAT-Luc construct (containing four NFAT binding sites; Stratagene, La Jolla, CA) using 5 μg DNA per 3x10 6 cells. Twenty-four hours post-transfection, Jurkat cells were transferred to the precoated plates at 2x10 5 cells per well and were stimulated for 6 h in RPMI 1640 medium containing 1%
FCS at 37°C/5% CO 2 . Stimulations with PMA (10 ng/ml) and ionomycin (1 μM) served as positive controls. After stimulation, cells were lysed with cell lysis buffer (Promega, Madison, WI), and luciferase activities were measured using chemiluminescent substrates according to the manufacturer's instructions (Promega). Samples were analyzed in a Gen-Probe Leader 50 luminometer (San Diego, CA) and luciferase activities were expressed as the percentage RLU of PMA/ionomycin controls.
Conjugate formation analysis
Mature monocyte-derived DCs (10 5 cells), pre-incubated for 20 min at 37°C with or without 1 μg/ml Staphylococcus Enterotoxin B (SEB, Sigma), were mixed with 10 6 PBL of an unrelated donor
For personal use only. on August 16, 2017. by guest www.bloodjournal.org From 8 and incubated for 15 or 60 min at 37°C with shaking. Where indicated, DC and PBL were preincubated for 30 min on ice with specific blocking antibodies prior to mixing. Antibodies remained present during cluster formation. The DC-PBL mixture was plated onto poly(L)lysine (50 μg/ml)-coated glass slides and incubated for 5 min at RT to let the cells adhere. Next, cells were fixed for 20 min at RT with 2% paraformaldehyde in PBS. Non-specific binding sites were blocked with blocking buffer (3% BSA, 10 mM glycine and 1% human serum in PBS) for 1 h at RT. Cells were triple stained with anti-ALCAM (AZN-L50, 1 μg/ml), anti-CD6 (5 μg/ml) and anti-LFA-1 (DF1524, 2.5 μg/ml), or anti-CD3 (T3b, 10 μg/ml), anti-CD6 (5 μg/ml) and anti-DC-SIGN (DCN46, 10 μg/ml) in blocking buffer for 1 h at RT, followed by incubation with Alexa Fluor 568-conjugated GαM-IgG2a, Alexa 
RESULTS

ALCAM is highly expressed on monocyte-derived DC and mediates adhesion to CD6
ALCAM-CD6 interactions are implicated in the formation of DC-T cell contacts. We investigated the expression levels of ALCAM on monocyte-derived DCs, relative to a panel of known DC markers. Mature DCs express ALCAM at levels comparable to maturation marker CD86 ( Figure   1A ). Upon maturation, ALCAM expression remains unchanged, while CD86 expression is significantly enhanced ( Figure 1B 
ALCAM-CD6 interactions are essential to promote proliferation of resting T cells induced by mature DCs
We analyzed the role of ALCAM and CD6 in T cell activation and proliferation induced by allogeneic mature DC and used freshly isolated total human PBLs as a T cell source. CD6 and ALCAM expression on these cells was measured by flowcytometry ( Figure 2A Figure 2C ). In addition, we measured proliferation at different time points (3, 5 and 7 days) after co-culture onset.
CD6 and LFA-1 antibodies were added at the beginning of the co-cultures ( Figure 2D ). The presence of CD6 antibodies resulted in a sustained repression of the proliferative response, even at seven days after addition of the antibodies. In contrast, LFA-1 antibodies inhibited proliferation at early time points but this effect was significantly decreased after five days of co-culture. These data indicate that ALCAM-CD6 mediated adhesion is important throughout the proliferation process, since the effect of blocking agents can be measured up to seven days after co-culture onset.
CD6 crosslinking enhances anti-CD3 induced T cell proliferation and activation of NFAT
We next investigated the co-stimulatory function of CD6 by inducing T cell proliferation with immobilized anti-CD3, anti-CD6 and anti-CD28, and combinations thereof. Co-crosslinking of CD3
and CD28 expectedly resulted in a strongly enhanced T cell proliferation compared with CD3 alone ( Figure 3A) . A similar effect was observed with CD3 and CD6 co-crosslinking. T cell proliferation was even further enhanced by simultaneous CD3, CD6 and CD28 crosslinking, while CD6 and CD28 alone hardly activated the T cells.
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We examined the observed co-stimulatory effect of CD6 in more detail by nucleofection of Jurkat T cells with an NFAT-luciferase reporter construct, followed by stimulation with immobilized anti-CD3, anti-CD6 and anti-CD28, and combinations thereof. First we determined a suboptimal anti-CD3 concentration (1 μg/ml) at which NFAT activation was still higher than background level (data not shown). In agreement with the observed effects on T cell proliferation, crosslinking of CD3 together with either CD28 or CD6 resulted in an increased NFAT activation compared with CD3 alone ( Figure 3B ). Simultaneous crosslinking of CD3 and CD6 also markedly increased activation of NFAT.
This CD6-mediated co-stimulatory effect could be directly correlated with the amount of antibody used. Simultaneous crosslinking of CD3, CD6 and CD28 did not further enhance NFAT activity in the presence of 1 μg/ml of anti-CD3. Apparently, maximal co-stimulation was reached already with anti-CD28 alone under these conditions. When lower quantities of anti-CD3 (0.2 μg/ml) were used, an additive effect of anti-CD6 and anti-CD28 was observed (data not shown).
ALCAM-CD6 interactions are important in the formation of DC-T cell contacts
Having assessed the effects of CD6-blocking antibodies and ALCAM-Fc molecules on mature DC-induced T cell proliferation, we next investigated the role of ALCAM-CD6 interactions at the initial phase of contact between mature DCs and resting T cells in an allogeneic setting. First, we determined the number of DC-T cell conjugates formed in the presence or absence of the superantigen SEB by confocal microscopy. SEB binds to the α1 domain of the HLA-DR1 molecule and is recognized by several isoforms of the human TCR Vβ, thereby implicating 20% of the T lymphocytes.
More DC-T cell contacts were observed in the presence than in the absence of SEB ( Figure 4A-B) Moreover, three out of five SEB-induced DC-T cell contacts showed enriched levels of CD6 ( Figure   4A , panels i-iii). Approximately 20% of the DCs formed a DC-T cell conjugate after 15 min incubation at 37°C ( Figure 4B ). Pre-treatment of the DCs with SEB increased the number of conjugates to 40% after 15 min, indicating that SEB accelerates stable DC-T cell conjugate formation.
After prolonged incubations of 60 min, differences between the presence and absence of SEB were no longer observed (data not shown). These findings confirm and extend previous results obtained with To determine if ALCAM-CD6 mediated adhesion is essential for the initiation of antigeninduced DC-T cell contacts we pre-incubated the DCs and T cells with blocking antibodies directed against ALCAM (AZN-L50 and J4-81) and CD6 prior to mixing. As a positive control for inhibition we used an LFA-1 blocking antibody. All antibodies remained present during the subsequent DC-T cell incubations. We also tested the effects of the antibodies on conjugate formation in the absence of SEB and found that none of them significantly reduced the number of antigen-independent DC-T cell contacts (data not shown). When ALCAM-blocking antibodies AZN-L50 and J4-81 were added separately, no significant effect on SEB-induced DC-T cell cluster formation was observed ( Figure   4C ). However, the combination of the two antibodies had an additive effect resulting in a significant block (~50%) of DC-T cell cluster formation, while anti-LFA-1 antibodies produced a block of about 66%. The presence of the anti-CD6 antibody did not affect the number of conjugates compared with the control situation, which may be explained by the fact that the latter antibody does not bind the ALCAM-binding region (the membrane-proximal SRCR domain) of CD6. This observation contrasts with the strong inhibitory effect of the anti-CD6 antibody on T cell proliferation and suggests that at least two distinct mechanisms are involved in DC-T cell binding versus T cell proliferation (see "Discussion"). Taken together, these observations point towards an important role for ALCAM-CD6 binding in the formation of DC-T cell contact.
Both ALCAM and CD6 are recruited at the contact site between T cells and DCs
A more detailed confocal analysis of the interface between mature DCs and resting T cells is presented in Figure 5 . ALCAM and CD6 accumulated and colocalized at the contact site between mature DCs and naïve T cells in the presence of SEB ( Figure 5A ). As expected, LFA-1 was also detected at the contact area. CD6 colocalized at least partially with CD3 at the T cell surface. In agreement with recent data 24 DC-SIGN, an important counter-receptor for ICAM-3 25 , did not concentrate at the DC-T cell interface ( Figure 5A ). The accumulation of CD6 in the immunological synapse was markedly enhanced in the presence of SEB ( Figure 5B ) and generally coincided with
For personal use only. on August 16, 2017. by guest www.bloodjournal.org From CD3 accumulation (data not shown). We subsequently analyzed the effect of blocking antibodies on the accumulation of CD6 at the DC-T cell interface ( Figure 5C ). Again, DCs and T cells were preincubated with blocking antibodies, which remained present during cluster formation. In the control situation, CD6 accumulation occurred in about 55% of the DC-T cell conjugates. Of the conjugates that were formed in the presence of ALCAM-blocking antibodies, only 20% still showed enriched CD6 levels at the contact site. The presence of anti-LFA-1 antibodies significantly reduced the number of T cell-APC conjugates ( Figure 4C ). However, in the remaining contacts CD6 accumulation in the synapse was present to the same extent as in the control situation ( Figure 5C ). These results suggest that CD6 is recruited towards the synapse independently of LFA-1.
Dynamic redistribution of ALCAM and CD6 at the T cell-APC interface
The dynamic behavior of ALCAM and CD6 at the T cell-APC contact site was studied by time-lapse confocal microscopy using Jurkat-CD6*RFP T cells and K562-ALCAM*GFP. Since K562 cells express moderate levels of HLA-DR/DP and CD80 (data not shown), they were used as a model APC in this experimental, antigen-independent setup. Interactions between Jurkat-CD6*RFP and K562-ALCAM*GFP were indeed ALCAM-mediated, since no conjugates were observed between Jurkat-CD6*RFP and parental K562 cells ( Figure 6A ). Both ALCAM and CD6 redistributed to the contact area between Jurkat-CD6*RFP and K562-ALCAM*GFP ( Figure 6B ). All initial Jurkat-CD6*RFP/K562-ALCAM*GFP contacts that gave rise to a stable conjugate were preceded by accumulation of ALCAM and CD6 at the cell-cell interface (Supplemental Movie 1A and 1B). We quantified the enrichment of ALCAM and CD6 at the contact site by calculating the recruitment index (RI), as indicated in Figure 6D , upper panel. Both molecules started to accumulate 6 min after initial contact. Their maximal RI value (~2.5-fold increased compared with the starting situation) was reached after 20 min and lasted for at least 60 min ( Figure 6D ). These findings show that ALCAM-CD6 binding is robust and implicate that ALCAM-CD6 mediated cell-cell interactions are also stable in vivo, which may relate to the observed long-lasting effects on T cell proliferation.
As known from previous reports, ALCAM not only interacts with CD6 but it also mediates homotypic ALCAM-ALCAM adhesion 7, 9, 10 . Accordingly, we observed homotypic ALCAM-ALCAM 
DISCUSSION
The work presented in this paper builds on previous observations by Gimferrer and colleagues who first showed that CD6 colocalizes with CD3 at the center of the immunological synapse and is involved in interactions needed for synapse maturation 20 . Here we confirm and extend their findings by demonstrating that CD6-ALCAM interactions are involved in both stabilization of DC-T cell contact and the second, proliferative phase of the T cell response. T cell proliferation is sustained for days by CD6-ALCAM binding, in which CD6 serves as an important co-stimulatory molecule. Both CD6 and ALCAM are actively recruited at the DC-T cell interface and localize all along the contact site. In contrast to transient, homotypic ALCAM-ALCAM interactions, CD6-ALCAM binding is robust and long-lasting, supporting the long-term effects observed on T cell proliferation.
Although comparable levels of ALCAM are present on immature and mature DCs, we observed a higher binding of mature DCs to CD6-Fc coated beads. This may be due to differences in plasma membrane distribution of ALCAM molecules induced by maturation. During DC development, rearrangement of receptor organization at the cell surface can occur, as has been reported for the C-type lectin DC-SIGN 26 . Dynamic redistribution of LFA-1 into clusters at the cell membrane increases its ligand binding potential 27, 28 . This phenomenon known as avidity regulation has also been implicated in ALCAM-mediated adhesion 9, 10 . The molecular organization of ALCAM at the DC surface at different developmental stages is currently under investigation.
Upon antigen-induced conjugate formation, CD6 and ALCAM are redistributed to the T cell-DC interface. CD6 partially colocalizes with CD3, in agreement with the previous finding that CD6 and CD3 colocalize in the central SMAC of the immunological synapse between Jurkat J77 and Raji B cells 20 . However, in the majority of the analyzed conjugates we found CD6 accumulation all along the contact region, suggesting that the presence of CD6 is not restricted to the cSMAC and that the peripheral SMAC also contains CD6. The localization of CD6 in both SMACs may relate to a dual function for CD6. It is tempting to speculate that CD6 in the pSMAC contributes to contact stabilization, similar to LFA-1 which is known to localize to the pSMAC upon synapse maturation 4 .
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Recruitment of CD6 and ALCAM at the T cell-APC interface started 6 minutes after contact initiation, similar to LFA-1 which is recruited within 4 minutes in the pSMAC 24 . However, CD6 accumulation in the synapse occurs independently of LFA-1 redistribution, since its relocalization was not affected by anti-LFA-1 antibodies. CD6 recruitment occurs significantly later than ICAM-3 which relocalizes in the synapse within 30 seconds 2 . ICAM-3 is already recruited before antigen-specific recognition occurs and induces MHC-II clustering into the immunological synapse 24 . In contrast to ICAM-3, CD6 recruitment appears to be at least partially antigen dependent since CD6 enrichment at the T cell-DC interface is markedly enhanced in the presence of antigen. Thus unlike ICAM-3, CD6
and ALCAM do not appear to be involved in the initial APC surface-scanning phase, but rather in stabilizing T cell-APC contacts after TCR-MHC binding has occurred. . We observed interesting differences between the effects of antibodies against CD6 and LFA-1, an adhesion molecule known to play a role in stabilization of the For personal use only. on August 16, 2017. by guest www.bloodjournal.org From immunological synapse and T cell co-stimulation 22, 29 . While CD6 blockade resulted in a complete inhibition of allogeneic DC-induced T cell proliferation, LFA-1 antibodies had only a partial effect.
Furthermore, the anti-CD6 induced block of proliferation was sustained for at least seven days, whereas the inhibitory effect of LFA-1 antibodies significantly decreased three days after initiation of the T cell-DC co-culture. These findings indicate that either the co-stimulatory signal provided by LFA-1 is short-lived or LFA-1 is merely involved in mediating contact. It has been reported that LFA-1 exerts its co-stimulatory function by facilitating and prolonging contact between an APC and T or B cell rather than by reducing the minimal number of TCRs that have to be triggered, as was reported for the prominent co-stimulatory receptor CD28 [30] [31] [32] . We show here that CD6 displays functional similarity with CD28, since CD6 crosslinking enhances CD3-induced proliferation and activation of NFAT comparable to CD28 crosslinking. These results validate and extend previous findings that simultaneous CD6 and CD3 crosslinking increases intracellular calcium levels and T cell proliferation [33] [34] [35] . Although CD28 is generally appreciated as the primary co-stimulatory receptor used by APC to augment T cell proliferation 36, 37 , we now show that CD6 blockade completely impaired DC-induced T cell proliferation up to seven days after activation. Thus, the function of CD6 may comprise the long-term maintenance and/or elevation of existing co-stimulatory signals, whereas CD28 may boost T cell co-stimulation at the early activation phase of the immune response.
Interestingly, the cytoplasmic domain of CD6 resembles that of CD28. Both contain multiple tyrosine residues that are not part of an ITAM motif, and proline-rich motifs that are able to recruit kinases of different families. Lck and Itk have been shown to bind to proline-rich motifs of both CD6 and CD28 19, 32 . However, Lck and Itk association with LFA-1 has not been reported. Itk activity is regulated by Lck 38 and is crucial for the production of second messengers that are required for a strong and sustained T cell activating signal. Furthermore it has been proposed that CD6 regulates tyrosine phosphorylation of CD5, another molecule involved in the regulation of signal transduction in T lymphocytes, by recruiting Lck, Itk, Fyn and ZAP-70 kinases 19 . Simultaneous association of different kinases that increase each other's activities may explain the strong effects of CD6 crosslinking we observed on T cell signaling and proliferation. 
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Association and co-operation of CD6 and CD5 may relate to our finding that the presence of CD6-blocking antibody that does not bind the ALCAM-binding region of CD6, still results in a dramatic block of T cell proliferation. We speculate that two different mechanisms involving CD6 may be operative during T cell activation and co-stimulation. First, CD6-ALCAM binding stabilizes DC-T cell contact and triggers CD6 activation. ALCAM-antibodies can effectively inhibit this step in vitro. Secondly, CD6 physically associates with CD5 at the plasma membrane and regulates CD5 tyrosine phosphorylation 19 . The presence of the anti-CD6 antibody may interfere with CD6-CD5 association and abrogate CD6-induced phosphorylation of CD5. It will therefore be interesting to study the effects of CD6 blockade on CD5-induced signaling pathways.
Taken together, the present study demonstrates that CD6-ALCAM interactions play a pivotal role in stabilizing the T cell-APC contacts. CD6 has a dual function in that it both facilitates stable adhesion and acts as a co-stimulatory molecule. Once the antigen-specific TCR-MHC contact has been established, CD6 is rapidly recruited to the T cell-APC interface where it stabilizes the immunological synapse by interacting with ALCAM. Subsequent CD6-modulated signaling events result in a strong and sustained co-stimulatory signal that is essential for T cell proliferation. Future research will be aimed at unraveling the molecular mechanisms underlying CD6-mediated signal transduction in order to fully understand its role as a co-stimulatory molecule.
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